Business Context and Reporting Period
Revolution Medicines, Inc. (RVMD) filed a Form 8-K on April 13, 2026, to report topline results from its Phase 3 RASolute 302 clinical trial. The trial evaluated daraxonrasib in patients with metastatic pancreatic ductal adenocarcinoma (PDAC) who had received prior treatment.
Key Financial Metrics
This filing is a Current Report (Item 8.01) focused on clinical trial results and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes and Clinical Results
The filing details statistically significant and clinically meaningful improvements for daraxonrasib compared to standard of care cytotoxic chemotherapy:
- Overall Survival (OS): Median OS was 13.2 months for daraxonrasib versus 6.7 months for chemotherapy (Hazard Ratio: 0.40; p < 0.0001).
- Progression-Free Survival (PFS): Statistically significant improvement reported, though specific median values were not detailed in the text.
- Safety: The drug was generally well tolerated with a manageable safety profile and no new safety signals.
- Study Status: Based on the first interim analysis, all PFS and OS endpoint results are considered final.
Guidance, Outlook, and Risks
Regulatory Strategy: The Company intends to submit these data to global regulatory authorities, including the U.S. Food and Drug Administration (FDA), as part of a future New Drug Application (NDA) utilizing a Commissioner's National Priority Voucher.
Risks and Uncertainties: The filing includes standard forward-looking statement disclaimers. Key risks include the inherent uncertainties of the drug development process, regulatory approval timelines, manufacturing challenges, intellectual property protection, capital resource sufficiency, and reliance on third-party partners.
Investor Verification Checklist
- Verify the specific median Progression-Free Survival (PFS) values and confidence intervals in the full clinical study report or press release.
- Confirm the timeline for the submission of the New Drug Application (NDA) to the FDA.
- Review the Company's most recent Form 10-K (filed February 25, 2026) for current cash runway and capital requirements to fund the NDA process.
- Assess the specific terms and conditions of the Commissioner's National Priority Voucher referenced for the NDA submission.